)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Spyre Therapeutics
Spyre Therapeutics (SYRE) investor relations material
Spyre Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary3 Nov, 2026
Executive summary
Q3 operating expenses rose 86% YoY to $105.7M and net loss widened to $96.1M from $11.2M, reflecting expanded clinical, manufacturing and compensation costs and a less favorable CVR revaluation.
SPY001, SPY002 and SPY003 met primary endpoints in SKYLINE UC Part A; SPY072 will not advance in rheumatic diseases after mixed-to-negative results.
October financing and post-quarter ATM sales support expected runway into H2 2029; SKYLINE combination enrollment is ahead of schedule.
Financial highlights
Q3 R&D was $89.2M vs. $45.2M YoY; G&A was $16.6M vs. $11.6M, and operating expenses totaled $105.7M vs. $56.9M.
Q3 net loss was $96.1M vs. $11.2M; common-stock loss per share was $0.94 vs. $0.15. Net cash used in operating activities was $77.5M.
Q3 total other income was $9.6M vs. $45.7M YoY, with the prior-year comparison affected by a CVR-liability fair-value change.
9M R&D was $215.1M vs. $127.0M, G&A was $47.9M vs. $35.4M, and net loss was $201.3M vs. $92.7M.
9M results included a $70.0M gain on the pegzilarginase asset sale vs. $10.0M in 2025; common-stock loss per share was $2.04 vs. $1.24.
Outlook and guidance
Existing liquidity, October 2026 offering proceeds and post-quarter ATM sales are expected to fund planned operating expenses and capital needs into H2 2029; estimates depend on assumptions that may prove inaccurate.
SKYLINE Part B induction results for three IBD combination programs are expected in Q3 2027; enrollment is ahead of schedule and the target enrollment has increased.
SKYLIGHT Week 16 topline results are planned for late 2027 or early 2028; potential SPY072 HS monotherapy pivotal studies are planned for 2027.
Operating losses are expected to increase with clinical development, manufacturing and pipeline investment; additional financing will be needed in the future.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Spyre Therapeutics
- Combination antibody therapies show promise in IBD, HS, and rheumatology, with pivotal SKYLINE data ahead.SYRE
Stifel 2026 Virtual Immunology and Inflammation Forum - Global trials of optimized biologic combinations in autoimmune diseases set up multiple late-stage catalysts.SYREWells Fargo 21st Annual Healthcare Conference
- Advancing innovative antibody combinations for autoimmune diseases with pivotal data expected in 2027.SYRECitigroup’s Biopharma Back to School Summit 2026
- Strong Phase 2 results and $1.15B cash position support ongoing R&D and clinical progress.SYREQ2 2026
- Multiple phase II readouts and novel combination therapies set to reshape autoimmune care.SYREGoldman Sachs 47th Annual Global Healthcare Conference 2026
- Six Phase 2 readouts in 2026 and $1.2B cash position drive next-gen immunology pipeline.SYRECorporate presentation
- Optimized antibody therapies for autoimmune diseases advance toward key phase II and III milestones.SYREJefferies Global Healthcare Conference 2026
- All proposals and director nominees were approved by preliminary vote at the virtual meeting.SYREAGM 2026
- Advancing anti-TL1A antibodies to Phase 2 with nine POC readouts expected by 2027.SYREStatus Update
Next Spyre Therapeutics earnings date
Q4 202619 Feb, 2027
Spyre Therapeutics
Next Spyre Therapeutics earnings date
Q4 202619 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Spyre Therapeutics Inc., previously known as Aeglea BioTherapeutics, is a clinical-stage biotechnology company. It specializes in developing therapeutics for inflammatory bowel disease (IBD), which includes conditions like ulcerative colitis and Crohn's disease. The company's focus is on creating novel and proprietary monoclonal antibody product candidates designed to address unmet needs in IBD care. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.